ICDD Preview Event 7 October 2021 03:00 – 05:00 PM CET

Chairs: Arjen Neven, psychiatrist, chair

Annette Bonebakker, clinical neuropsychologist

Tony Bloemendaal, clinical psychologist – psychotherapist

03:00 Welcome and introduction

Annette Bonebakker, clinical neuropsychologist, Fivoor

O3:15 ADHD and substance use disorder, what have we learned over the past decade of research? Arnt Schellekens, Professor of Addiction Psychiatry, Radboudumc, the Netherlands

ADHD ans substance use disorders often co-occur and co-occurrence of these conditions has a negative impact on the course of both conditions. Yet, ADHD is still too often overlooked or ignored. An increasing scientific interest in these conditions over the past decade has furthered our understanding of this frequent comorbidity in psychiatry and yielded directions for clinical practice with regard to the diagnostic process and treatment. This lecture will provide an overview of developments in this field over the past decade, including shared heritability, reliability of the diagnostic process and effectiveness of different pharmacotherapies, including high-dose stimulant treatment.

03:45 T.B.A.

Geert Dom, Psychiatrist, University of Antwerp, Belgium

04:15 Integrated Dual Disorder Treatment: Looking Forward After Twenty Years of Implementation Patrick Boyle, Consulting Director, Center for Evidence-Based Practices, Case Western Reserve University, USA

Integrated Dual Disorder Treatment (IDDT) was researched and developed during the 1990's and implemented as an integrated clinical practice to help people with co-occurring mental illness and substance use disorders live full lives in an evolving recovery process (Drake, Goldman, et al 2001). While such evidence based practices have become more widely implemented across the world during the past twenty years, people with these two co-occurring disorders are still at risk of not receiving fully integrated care services for many reasons. Read more..

04:45 Closing